Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT EMM21 fixed-duration sequential therapy with DRd, autologous stem cell transplantation, and ixazomib maintenance in newly diagnosed elderly multiple myeloma
jRCTs071210084Phase 2Active, not recruiting
- Sponsor
- Kyushu University Hospital
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, lenalidomide, dexamethasone, plerixafor, melphalan and 2 more in multiple myeloma (MM), sponsored by Kyushu University Hospital. Primary endpoint: 2-year progression-free survival rate. Started Dec 2021; status: active, not recruiting.
02
Drugs
daratumumablenalidomidedexamethasoneplerixaformelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071210084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210084.